Notice NOT-TW-23-006 from the NIH Guide for Grants and Contracts

Notice NOT-TW-23-005 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-024 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-325 from the NIH Guide for Grants and Contracts

Notice NOT-AA-23-012 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-23-172 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This R34 Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.

Funding Opportunity PAS-23-173 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.

Notice NOT-AI-23-047 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-023 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-177 from the NIH Guide for Grants and Contracts. The National Center for Advancing Translational Sciences (NCATS) invites applications for the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) Funding Opportunity Announcement (FOA) to foster investigator-initiated development of highly innovative technologies to address barriers, limitations, or bottlenecks in translational science particularly for therapeutic development. This program will support the early-stage proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development, which can transform or significantly improve the efficiency of therapeutic development to achieve NCATS ultimate goals - more treatments to all people more quickly. The research proposed should be for the development of technology that can break new ground or extend present technology toward new directions or novel applications. With this initiative, we expect to support the development and/or prototyping of new technologies that will lead to improved efficiency in the therapeutic development pipeline.

Funding Opportunity PAR-23-174 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to provide dissertation awards in all areas of research within NIAs strategic priorities to promote the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.

Notice NOT-DC-23-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-24-017 from the NIH Guide for Grants and Contracts. The Longevity Consortium (LC) originally established in 2004, is one of a group of ongoing human longevity translational projects employing a variety of approaches for the identification and translation of protective genomic and other factors associated with exceptional longevity. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit a cooperative agreement (U19) application for the renewal of the LC.

Notice NOT-MD-23-013 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-191 from the NIH Guide for Grants and Contracts. The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH), including exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities ( https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html; https://www.oar.nih.gov/hiv-policy-and-research/research-priorities). Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field. U.S. and LMIC investigators are eligible to apply for collaborative projects to be done at LMIC sites; however, a U.S. investigator must apply together with an LMIC investigator. LMICs are defined by the World Bank classification system according to Gross National Income (GNI) per capita as low-income, lower-middle-income, and upper-middle-income (http://data.worldbank.org/about/country-classifications/country-and-lending-groups).

Funding Opportunity PAR-23-190 from the NIH Guide for Grants and Contracts. To develop and/or pilot test interventions for HIV/AIDS-associated stigma and its outcome on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on or leading to interventions to address a) innovation in measurement of HIV-associated stigma and of other intersecting stigmas due to multiple morbidities to develop better interventions, b) stigma and adolescent and/or youth health, c) effects of stigma on family members or care givers of PLWH, and on the aging PLWH, d) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission and e) coping with the complexity of added burden of stigmatization due to HIV and to one or more comorbidities/coinfections.

Notice NOT-HD-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-015 from the NIH Guide for Grants and Contracts. This concept would support the development of pain clinical trainees as a means of enhancing the clinical pain workforce. It would fund 4 clinical pain T90/R90s that would provide robust post-doctoral fellowship research training in areas of clinical pain management that would benefit from further research. The T90/R90 mechanism is a NRSA program that supports comprehensive interdisciplinary research training programs at the undergraduate, predoctoral, and/or post-doctoral levels by capitalizing on the infrastructure of existing multidisciplinary and interdisciplinary research programs. The HEAL T90/R90 program would focus on training post-doctoral fellows with T90 trainees being those who are NRSA eligible and R90 trainees (maximum of 1 per award per year) being those who do not meet qualifications for NRSA support (including non-US citizens or residents). Trainees would either need to have a clinical degree or have a non-clinical degree but are interested in conducting clinical pain research. The T90/R90 training programs would provide mentoring and training to promote the successful transition of the trainees to independent research careers in academic or government settings. Unlike the T32 mechanism, the T90/R90 mechanism would support the dedication of 10% of the programs mentors time to mentoring the next generation of clinical pain researchers. The newly funded T90/R90s would work in coordination with the HEAL R24 Coordinating Center to ensure that trainees participate in the network, collaborative events/webinars, build relationships with basic and clinical science trainees, and attend the annual workshop. The NIH will prioritize funding T90/R90s universities and institutions that do not currently have a pain T32 or have not previously received funding for a pain T32. T90/R90 applicants are encouraged to partner with another university or institution to help increase the interdisciplinary nature of the mentors and trainees.

Funding Opportunity PAR-23-180 from the NIH Guide for Grants and Contracts. The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.